T-knife Therapeutics
Latest round
- Series B
Last raised
- Apr 2021
Total raised
- $188M
Investors
- 10
About T-knife Therapeutics
Based in Delaware, US, and founded in 2018 by CEO Thomas Blankenstein and CTO Elisa Kieback, T-Knife GmbH is a biopharmaceutical firm that creates treatments for T cell receptors (TCRs). T-Knife GmbH secured USD 110 million in Series B investment sponsored by Fidelity Investments in August 2021. The company is a T-cell receptor (TCR) firm that is developing a pipeline of novel medicines for patients with solid tumors. T-knife is leveraging its proprietary HuTCR transgenic mouse platform to discover and develop a portfolio of TCR-T programs to treat patients with solid tumors. The company’s lead program, TK-8001, is a novel TCR-T product targeting MAGE-A1-positive cancers. T-knife is also developing a pipeline of potential TCR therapeutics against targets with unmet medical needs, including cancer-testis antigens, viral antigens, and commonly shared neoantigens.
Who invested in T-knife Therapeutics
10 investors across 2 rounds
See all investors in T-knife Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about T-knife Therapeutics
Who invested in T-knife Therapeutics?
T-knife Therapeutics has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has T-knife Therapeutics raised?
T-knife Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did T-knife Therapeutics last raise money?
T-knife Therapeutics's most recent round on record is a Series B, in Apr 2021.
What does T-knife Therapeutics do?
Based in Delaware, US, and founded in 2018 by CEO Thomas Blankenstein and CTO Elisa Kieback, T-Knife GmbH is a biopharmaceutical firm that creates treatments for T cell receptors (TCRs).
Where is T-knife Therapeutics headquartered?
T-knife Therapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like T-knife Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at T-knife Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like T-knife Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.